Application of antimicrobial stewardship to optimise management of community acquired pneumonia

International Journal of Clinical Practice

Volumn 65, Issue 7, 2011, Pages 775-783

  Bosso, J A ^a   Drew, R H ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CAMPBELL UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AWARENESS; CLINICAL PATHWAY; COMMUNITY ACQUIRED PNEUMONIA; DRUG TREATMENT FAILURE; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL PATHWAYS; DRUG RESISTANCE, MICROBIAL; DRUG SUBSTITUTION; GUIDELINE ADHERENCE; HUMANS; INFUSIONS, INTRAVENOUS; MEDICAL INFORMATICS; PHARMACEUTICAL SERVICES; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN;

EID: 79959307342     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02704.x     Document Type: Review

References (38)

1. Niederman MS,. Community-acquired pneumonia: management controversies, part 1; practical recommendations from the latest guidelines. J Respir Dis 2002; 23: 10-7.
2. Niederman MS, Mandell LA, Anzueto A, et al., American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-54. (Pubitemid 32578779)
3. Woodhead M, Welch CA, Harrison DA, et al., Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006; 10 (Suppl. 2): S1.
4. Colice GL, Morley MA, Asche C, et al., Treatment costs of community-acquired pneumonia in an employed population. Chest 2004; 125: 2140-5. (Pubitemid 38788182)
5. Stanton MW,. Improving treatment decisions for patients with community-acquired pneumonia. Agency for Healthcare Research and Quality. Res Act 2002; Issue 7. Publication No. 02-0033.
6. Benninger M, Segreti J,. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J Fam Pract 2008; 57: S5-11. (Pubitemid 351379195)
7. Mandell LA, Wunderink RG, Anzueto A, et al., Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27-72. (Pubitemid 46290553)
8. Zhanel GG, Palatnick L, Nichol KA, et al., Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867-74. (Pubitemid 36637807)
9. Jenkins SG, Brown SD, Farrell DJ,. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008; 7: 1.
10. Adam HJ, Hoban DJ, Gin AS, et al., Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009; 34: 82-5.
11. Thornsberry C, Brown NP, Draghi DC, et al., Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgrad Med 2008; 3 (Suppl. 1): 32-8.
12. Lautenbach E, Metlay JP, Weiner MG, et al., Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009; 30: 18-24.
13. Lockhart SR, Abramson MA, Beekmann SE, et al., Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45: 3352-9. (Pubitemid 47585661)
14. Hageman JC, Uyeki TM, Francis JS, et al., Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9. (Pubitemid 43848409)
15. Siegel RE,. Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care 2008; 53: 471-9.
16. Linder JA, Huang ES, Steinman MA, et al., Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118: 259-68. (Pubitemid 40312637)
17. Neuhauser MM, Weinstein RA, Rydman R, et al., Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-8. (Pubitemid 37430348)
18. Polk RE, Johnson CK, McClish D, et al., Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39: 497-503. (Pubitemid 39120924)
19. Cosgrove SE, Qi Y, Kaye KS, et al., The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-74. (Pubitemid 40445022)
20. Cosgrove SE,. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42 (Suppl. 2): S82-9. (Pubitemid 43054219)
21. Spellberg B, Guidos R, Gilbert D, et al., Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-64. (Pubitemid 351269151)
22. MacDougall C, Polk RE,. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18: 638-56. (Pubitemid 41504509)
23. Dellit TH, Owens RC, McGowan JE Jr, et al., Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77. (Pubitemid 46084814)
24. Drew RH, White R, MacDougall C, et al., Society of Infectious Diseases Pharmacists. Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy 2009; 29: 593-607.
25. Athanassa Z, Makris G, Dimopoulos G, et al., Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 2008; 68: 2469-81.
26. Oosterheert JJ, Bonten MJ, Schneider MM, et al., Effectiveness of early switch from intravenous to oral antibiotics in severe community-acquired pneumonia: multicentre randomised trial. BMJ 2006; 333: 1193.
27. Ramirez JA, Vargas S, Ritter GW, et al., Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54. (Pubitemid 29526773)
28. Nathan RV, Rhew DC, Murray C, et al., In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119: 512.
29. Marrie TJ, Lau CY, Wheeler SL, et al., A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749-55. (Pubitemid 30084614)
30. Marrie TJ,. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia. Chemotherapy 2004; 50 (Suppl. 1): 11-5. (Pubitemid 39179215)
31. Hauck LD, Adler LM, Mulla ZD,. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol 2004; 14: 669-75. (Pubitemid 39233628)
32. Hagaman JT, Yurkowski P, Trott A, et al., Getting physicians to make "the switch": the role of clinical guidelines in the management of community-acquired pneumonia. Am J Med Qual 2005; 20: 15-21. (Pubitemid 40879700)
33. Blasi F, Iori I, Bulfoni A, et al., Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J 2008; 32: 902-10.
34. Capelastegui A, España PP, Quintana JM, et al., Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004; 39: 955-63. (Pubitemid 39313450)
35. Orrick JJ, Segal R, Johns TE, et al., Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 2004; 22: 751-7. (Pubitemid 38998499)
36. Davydov L, Ebert SC, Restino M, et al., Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. Diagn Microbiol Infect Dis 2006; 54: 267-75.
37. Schouten JA, Hulscher ME, Trap-Liefers J, et al., Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis 2007; 44: 931-41. (Pubitemid 46452057)
38. Wong-Beringer A, Nguyen LH, Lee M, et al., An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy 2009; 29: 736-43.